
PVLA Stock Forecast & Price Target
PVLA Analyst Ratings
Bulls say
Palvella Therapeutics Inc demonstrates a promising outlook based on data indicating an average potential share price increase of 168% across various scenarios. The successful clinical trial results for QTORIN rapamycin show significant improvements on key endpoints, including a 3.36-point enhancement in the mLM multi-component static scale, which could lead to increased compliance due to substantial symptom relief in patients. Furthermore, the positive results from clinician and patient-reported outcome measures support the potential for favorable acceptance among prescribers and payors, reinforcing the company's strategic position in the market for rare genetic skin diseases.
Bears say
Palvella Therapeutics faces significant financial challenges that contribute to a negative outlook on its stock. The potential for lower-than-projected pricing for QTORIN rapamycin could substantially diminish its commercial viability, even with regulatory approval, compounded by the uncertainty surrounding patient access and onboarding, which might hamper long-term market penetration. Furthermore, the company may require additional capital, potentially through equity financing, leading to share dilution for existing shareholders before achieving profitability.
This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PVLA Analyst Forecast & Price Prediction
Start investing in PVLA
Order type
Buy in
Order amount
Est. shares
0 shares